Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

Qin C. Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B. Trepel, Joseph Ye, William D. Figg, Kyunghwa Hwang, Eun Joo Chung, Anthony Murgo, Giovanni Melillo, Yusri Elsayed, Manish Monga, Mikhail Kalnitskiy, James Zwiebel, Edward A. Sausville*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

379 Scopus citations

Abstract

Purpose: The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275. Patients and Methods: Patients with advanced solid tumors or lymphoma were treated with MS-275 orally initially on a once daily × 28 every 6 weeks (daily) and later on once every-14-days (q 14-day) schedules. The starting dose was 2 mg/m2 and the dose was escalated in three- to six-patient cohorts based on toxicity assessments. Results: With the daily schedule, the MTD was exceeded at the first dose level. Preliminary PK analysis suggested the half-life of MS-275 in humans was 39 to 80 hours, substantially longer than predicted by preclinical studies. With the q14-day schedule, 28 patients were treated. The MTD was 10 mg/m2 and dose-limiting toxicities were nausea, vomiting, anorexia, and fatigue. Exposure to MS-275 was dose dependent, suggesting linear PK. Increased histone H3 acetylation in peripheral-blood mononuclear-cells was apparent at all dose levels by immunofluorescence analysis. Ten of 29 patients remained on treatment for ≥ 3 months. Conclusion: The MS-275 oral formulation on the daily schedule was intolerable at a dose and schedule explored. The q14-day schedule is reasonably well tolerated. Histone deacetylase inhibition was observed in peripheral-blood mononuclear-cells. Based on PK data from the q14-day schedule, a more frequent dosing schedule, weekly × 4, repeated every 6 weeks is presently being evaluated.

Original languageEnglish
Pages (from-to)3912-3922
Number of pages11
JournalJournal of Clinical Oncology
Volume23
Issue number17
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Dive into the research topics of 'Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma'. Together they form a unique fingerprint.

Cite this